<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AZACITIDINE</span><br/>(a-za-ci'ti-deen)<br/><span class="topboxtradename">Vidaza<br/></span><b>Classifications:</b> <span class="classification">antineoplastic agent</span>; <span class="classification">antimetabolite (pyrimidine)</span><br/><b>Prototype: </b>Fluorouracil<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Causes changes in DNA in abnormal blood-forming cells in the bone marrow, resulting in restoration of normal function to tumor-suppressor
         genes that are responsible for regulating cell differentiation and growth.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The cytotoxic effects of azacitidine cause the death of rapidly dividing cancer cells that are no longer responsive to normal
         growth control mechanisms.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of myelodysplastic syndrome, specifically refractory anemia.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Refractory acute lymphocytic and myelogenous leukemia</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to azacitidine or mannitol; advanced malignant hepatic tumors, myelodysplastic syndrome with hepatic
         impairment; vaccination; active infection; dental work; intramuscular injections, if platelets 3; pregnancy (category D), lactation. Safety and efficacy in children have not been established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypoalbuminemia (
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Myelodysplastic Syndrome</span><br/><span class="rdage">Adult<i></i>
                  				:</span> <span class="rdroute">SC</span> 75 mg/m<sup>2</sup> once daily for 7 d every 4 wk; may increase to 100 mg/m<sup>2</sup> if no beneficial response is seen after 2 treatment cycles and no toxicity other than nausea and vomiting has occurred<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>If unexplained elevations of BUN or creatinine occur, the next cycle should be delayed until the values return to normal or
               baseline, and the dose should be reduced by 50% in the next course<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">
<b>Subcutaneous</b>
</span><br/><ul>
<li>Reconstitute by slowly injecting 4 mL of sterile water for injection into 100 mg vial to yield 25 mg/mL. Invert 23 times
            and gently rotate until a uniform suspension is achieved. The suspension will be cloudy. If not used immediately, see directions
            for storage.
         </li>
<li>Doses greater than 4 mL should be divided equally into 2 syringes and injected into 2 separate sites. Rotate sites for each
            injection (thigh, abdomen, or upper arm). Give subsequent injections at least 1 in from an old site and never into areas where
            the site is tender, bruised, red, or hard.
         </li>
<li>Storage: Reconstituted suspension may be kept in the vial or syringe. May refrigerate for up to 8 h. Before use, suspension
            may be kept at room temperature for up to 30 min. Resuspend by inverting the syringe 23 times and gently roll between
            the palms for 30 sec immediately before administration.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Fever, fatigue, malaise, weakness, asthenia, limb pain, back pain</span>
<i>,</i> lymphadenopathy, hematoma, night sweats, cellulitis, lethargy. <span class="typehead">CNS:</span>
<span class="speceff-common">Dizziness, headache, depression</span>
<i>,</i> syncope. <span class="typehead">CV:</span>
<span class="speceff-common">Chest pain</span>
<i>,</i> cardiac murmur, tachycardia, hypotension. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea, constipation, anorexia, weight loss, abdominal pain</span>
<i>,</i> stomatitis, dyspepsia. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Anemia, thrombocytopenia, leukopenia, neutropenia, ecchymosis, febrile neutropenia</span>
<i>.</i>
<span class="typehead">Metabolic:</span>
<span class="speceff-common">Peripheral edema</span>
<i>.</i>
<span class="typehead">Musculoskeletal:</span>
<span class="speceff-common">Myalgia, arthralgia</span>
<i>,</i> muscle cramps.  <span class="typehead">Respiratory:</span>
<span class="speceff-common">Cough, dyspnea, pharyngitis, nasopharyngitis, pneumonia</span>
<i>,</i> wheezing, pleural effusion, rhonchi. <span class="typehead">Skin:</span>
<span class="speceff-common">Injection site erythema, injection site reactions, rash, pruritus, sweating</span>
<i>,</i> urticaria.  <span class="typehead">Urogenital:</span> Dysuria, urinary tract infection. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">anticoagulants, nsaids, antiplatelet agents</span> may increase risk of bleeding; <b>filgrastim, sargramostim</b> may interfere with the efficacy of azacitidine if given within 24 h of azacitidine dose. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Peak:</span>  30 min. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted by kidneys. <span class="typehead">Half-Life:</span> 4 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">
<b>Assessment &amp; Drug Effects</b>
</span></p>
<ul>
<li>Monitor for S&amp;S of drug toxicity in those with renal insufficiency.</li>
<li>Lab tests: Obtain LFTs and serum creatinine before initiation of therapy; monitor CBC with differential before each treatment
            cycle and prn.
         </li>
<li>Withhold drug &amp; notify physician for S&amp;S of hepatic or renal insufficiency; lab values that indicate leukopenia, neutropenia,
            thrombocytopenia, or hepatic or renal insufficiency; or serum bicarbonate levels less than 20 mEq/L.
         </li>
</ul>
<p><span class="eductitle">
<b>Patient &amp; Family Education</b>
</span></p>
<ul>
<li>Promptly report S&amp;S of infection or indication of unusual bleeding tendencies (e.g., dark, tarry stools and easy bruising).</li>
<li>Women should avoid becoming pregnant and men should not father a child while taking this drug.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>